{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:39:34Z","timestamp":1789648774942,"version":"4.0.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:p> Bazedoxifene is a third-generation selective estrogen-receptor modulator being developed for use alone or in combination with estrogen for prevention and treatment of osteoporosis in postmenopausal women. Preliminary clinical trials are encouraging. Bazedoxifene has been found to be efficacious in reducing bone turnover without adverse effects of breast pain. In Phase III studies, bazedoxifene was found to increase vasomotor symptoms when compared with placebo. This effect is similar to that of raloxifene. Lack of endometrial stimulation is another advantage. Current literature suggests that bazedoxifene is likely to be safe, well tolerated and effective for the treatment of postmenopausal osteoporosis. However, completion of Phase III clinical trials will further elucidate its safety and efficacy, as well as its advantages in comparison with other selective estrogen-receptor modulators. <\/jats:p>","DOI":"10.2217\/17455057.4.4.319","type":"journal-article","created":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T11:37:45Z","timestamp":1232365065000},"page":"319-326","source":"Crossref","is-referenced-by-count":4,"title":["Bazedoxifene: A Selective Estrogen-Receptor Modulator"],"prefix":"10.1177","volume":"4","author":[{"given":"Mohamed FM","family":"Mitwally","sequence":"first","affiliation":[{"name":"University of New Mexico, Division of Reproductive Endocrinology & Infertility, Department of Obstetrics & Gynecology, Albuquerque, New Mexico, USA, Tel.: +1 719 475 2229; Fax: +1 719 475 2227;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2008,7,1]]},"reference":[{"key":"bibr100-17455057.4.4.319","unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022\u2022) to readers."},{"key":"bibr1-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra022219"},{"key":"bibr34-17455057.4.4.319","unstructured":"Reviews the concepts behind the use of selective estrogen-receptor modulators in clinical practice for osteoporosis management and other indications."},{"key":"bibr2-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H428"},{"key":"bibr35-17455057.4.4.319","unstructured":"Reviews the available literature regarding bazedoxifene as one of the promising selective estrogen-receptor modulators in clinical practice for osteoporosis management."},{"key":"bibr3-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.785"},{"key":"bibr4-17455057.4.4.319","volume-title":"Bone Health and Osteoporosis: a Report of the Surgeon General","author":"US Department of Health and Human Services","year":"2004"},{"key":"bibr36-17455057.4.4.319","unstructured":"Important reference highlighting the economic impact of osteoporosis management, and both direct and indirect costs associated with osteoporosis treatment."},{"key":"bibr5-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.23.3.0465"},{"key":"bibr6-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1097\/01.GME.0000086467.82759.DA"},{"key":"bibr7-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000222475.93345.b3"},{"key":"bibr37-17455057.4.4.319","unstructured":"Outlines the available management modalities for osteoporosis including options for prevention and treatment."},{"key":"bibr8-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342040-00004"},{"key":"bibr9-17455057.4.4.319","volume-title":"Evista\u00ae (raloxifene hydrochloride), package insert","year":"2003"},{"key":"bibr10-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb04039.x"},{"key":"bibr11-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1021\/jm010086m"},{"key":"bibr12-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0030"},{"key":"bibr38-17455057.4.4.319","unstructured":"Addresses the potential for developing bazedoxifene for managing osteoporosis in postmenopausal women."},{"key":"bibr13-17455057.4.4.319","volume":"73","author":"Patat A","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"bibr14-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)90527-3"},{"key":"bibr15-17455057.4.4.319","volume":"73","author":"Chandrasekaran A","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"bibr16-17455057.4.4.319","first-page":"1086","volume":"5","author":"Gruber C","year":"2004","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"bibr17-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb04039.x"},{"key":"bibr18-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0030"},{"key":"bibr19-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000163253.27610.b9"},{"key":"bibr20-17455057.4.4.319","unstructured":"Ronkin S, Baracat E, Roma L, TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. Presented at: 83rd Annual Meeting of the Endocrine Society. Denver, CO, USA, 20\u201323 June 2001 489 (Abstract P3\u2013145)."},{"key":"bibr21-17455057.4.4.319","first-page":"S14","volume":"14","author":"Boudes P","year":"2003","journal-title":"Osteoporos. Int."},{"key":"bibr22-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000163253.27610.b9"},{"key":"bibr23-17455057.4.4.319","first-page":"S413","volume":"16","author":"Ronkin S","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"bibr24-17455057.4.4.319","first-page":"S14","volume":"14","author":"Boudes P","year":"2003","journal-title":"Osteoporos. Int."},{"key":"bibr39-17455057.4.4.319","unstructured":"Presents important clinical information on occurrence of breast pain while administering bazedoxifene in managing postmenopausal osteoporosis."},{"key":"bibr25-17455057.4.4.319","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.071206"},{"key":"bibr40-17455057.4.4.319","unstructured":"Presents important clinical information and strong evidence from level 1 evidence-based information on the success of bazedoxifene in managing postmenopausal osteoporosis."},{"key":"bibr101-17455057.4.4.319","unstructured":"National Osteoporosis Foundation. www.nof.org"},{"key":"bibr102-17455057.4.4.319","unstructured":"International Osteoporosis Foundation. Osteoporosis and you. www.osteofound.org\/publications\/pdf\/osteoporosis_and_you.pdf"},{"key":"bibr103-17455057.4.4.319","unstructured":"National Osteoporosis Foundation 2006 America's bone health: the state of osteoporosis and low bone mass. www.nof.org\/advocacy\/prevalence\/indexed.htm (Accessed 29 January 2007)."},{"key":"bibr200-17455057.4.4.319","unstructured":"Addresses the demographics and public significance of osteoporosis."},{"key":"bibr104-17455057.4.4.319","unstructured":"Tamoxifen drug information. www.fda.gov\/cder\/foi\/label\/2005\/17970s053lbl.pdf (Accessed 11 January 2007)."},{"key":"bibr105-17455057.4.4.319","unstructured":"Fracture incidence reduction and safety of TSE-424 (bazedoxifene acetate) compared to placebo and raloxifene in osteoporotic postmenopausal women. (Identifier: NCT00205777). www.clinicaltrials.gov Search term \u2018bazedoxifene\u2019 (Accessed 16 June 2006)."},{"key":"bibr201-17455057.4.4.319","unstructured":"Presents important clinical information and strong evidence on the success of bazedoxifene in managing postmenopausal osteoporosis."},{"key":"bibr106-17455057.4.4.319","unstructured":"Bone mineral density increase and safety of TSE-424 compared to placebo in osteoporotic postmenopausal women. (Identifier: NCT00238745). www.clinicaltrials.gov"},{"key":"bibr202-17455057.4.4.319","unstructured":"Search term \u2018bazedoxifene\u2019 (Accessed 16 June 2006)."},{"key":"bibr203-17455057.4.4.319","unstructured":"Presents important clinical information and strong evidence on the success of bazedoxifene in managing postmenopausal osteoporosis."},{"key":"bibr107-17455057.4.4.319","unstructured":"A double-blind, randomized, placebo-controlled, efficacy and safety study of bazedoxifene\/conjugated estrogen combinations for treatment of vasomotor symptoms associated with menopause. (Identifier: NCT00234819). www.clinicaltrials.gov Search term \u2018bazedoxifene\u2019 (Accessed 16 June 2006)."},{"key":"bibr204-17455057.4.4.319","unstructured":"Presents important clinical information and strong evidence on the success of bazedoxifene in managing postmenopausal vasomotor symptoms."},{"key":"bibr108-17455057.4.4.319","unstructured":"A double-blind, randomized, placebo- and active-controlled efficacy and safety study of bazedoxifene\/conjugated estrogens combinations for prevention of endometrial hyperplasia and prevention of osteoporosis in postmenopausal women. (Identifier: NCT00242710). www.clinicaltrials.gov Search term \u2018bazedoxifene\u2019 (Accessed 16 June 2006)."},{"key":"bibr205-17455057.4.4.319","unstructured":"Presents important clinical information and strong evidence on the success of bazedoxifene in managing postmenopausal osteoporosis."},{"key":"bibr109-17455057.4.4.319","unstructured":"A double-blind, randomized, placebo- and active-controlled efficacy and safety study of bazedoxifene\/conjugated estrogens combinations for treatment of moderate to severe vulvar\/vaginal atrophy in postmenopausal women. (Identifier: NCT00238732). www.clinicaltrials.gov Search term \u2018bazedoxifene\u2019 (Accessed 16 June 2006)."},{"key":"bibr206-17455057.4.4.319","unstructured":"Presents important clinical information and strong evidence on the success of bazedoxifene in managing postmenopausal symptoms of vaginal atrophy."}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.4.4.319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/17455057.4.4.319","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.4.4.319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T12:48:25Z","timestamp":1741610905000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/17455057.4.4.319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.2217\/17455057.4.4.319"],"URL":"https:\/\/doi.org\/10.2217\/17455057.4.4.319","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"value":"1745-5057","type":"print"},{"value":"1745-5065","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}